Vanda Pharmaceuticals Inc
For the period ended May 7, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 7, 2025 · Filed May 7, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Early-Stage Program Highlights
Early-Stage Program Highlights
VQW-765, an alpha-7 nicotinic acetylcholine receptor partial agonist, is currently in clinical development for the treatment of acute performance anxiety in social situations. Vanda expects to initiate the Phase III program in 2025.
The IND application for VCA-894A in the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), an inherited peripheral neuropathy for which there is no available treatment, was accepted by the FDA in 2024. Previously in 2023, VCA-894A was granted Orphan Drug Designation for the same indication. The Phase I clinical study for VCA-894A expects to enroll the patient by mid-2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.